



Opioids at the health and transportation safety nexus

December 2019

Rebecca B. Naumann

Kristin Shiue

Stephen W. Marshall

University of North Carolina at Chapel Hill

Amin M. Hezaveh

Christopher R. Cherry

University Name

U.S. DOT Disclaimer

The contents of this report reflect the views of the authors, who are responsible for the facts and the accuracy of the information presented herein. This document is disseminated in the interest of information exchange. The report is funded, partially or entirely, by a grant from the U.S. Department of Transportation's University Transportation Centers Program. However, the U.S. Government assumes no liability for the contents or use thereof.

Acknowledgement of Sponsorship

This project was supported by the Collaborative Sciences Center for Road Safety, www.roadsafety.unc.edu, a U.S. Department of Transportation National University Transportation Center promoting safety.

Prior Publication

A version of this work was published in the American Journal of Preventive Medicine. The recommended citation for that work is:

Naumann, R.B. , K. Shuiue, A.M. Hezaveh, S.W. Marshall, and C.R. Cherry. 2020. "Connections between opioids and road injury: linkage of prescription monitoring and crash databases." *American Journal of Preventive Medicine*.

TECHNICAL REPORT DOCUMENTATION PAGE

1. Report No. CSCRS-R16	2. Government Accession No.	3. Recipient's Catalog No.	
4. Title and Subtitle: Opioids at the health and transportation safety nexus		5. Report Date December 2019	
		6. Performing Organization Code	
7. Author(s) Rebecca B. Naumann; Kristin Shiue; Stephen W. Marshall; Amin M. Hezaveh; Christopher R. Cherry		8. Performing Organization Report No.	
9. Performing Organization Name and Address University of Tennessee, Knoxville University of North Carolina, Chapel Hill		10. Work Unit No.	
		11. Contract or Grant No. R16	
12. Sponsoring Agency Name and Address		13. Type of Report and Period Covered Final Report	
		14. Sponsoring Agency Code R16	
15. Supplementary Notes Conducted in cooperation with the U.S. Department of Transportation, Federal Highway Administration.			
16. Abstract <p><i>Background:</i> Drug overdoses and motor vehicle (MV) crashes are leading causes of unintentional injury death in the US, resulting in over 100,000 fatalities in 2017. Research has established that opioids affect driving ability and that crash-related injuries often result in opioid prescribing. Despite known associations, current approaches for studying these intertwined public health problems typically involve separate analyses using discrete databases.</p> <p><i>Purpose:</i> To assess collection of relevant data elements and evaluate the linkage potential of prescription drug monitoring programs (PDMP) with crash databases, and to determine knowledge gaps that can be addressed through effective linkage.</p> <p><i>Methods:</i> Standardized templates were used to abstract specific data elements and attributes of MV crash and PDMP databases for all 50 states and DC. Abstracted PDMP elements included accessibility of PDMP data and schedules of controlled substances monitored in each state, while crash-related elements included whether crash reports document the type of drug test administered at the scene and the granularity of test results recorded.</p> <p><i>Results:</i> A majority of PDMPs (94%) are authorized to release data for research purposes. Schedules II-V controlled substances are tracked in 76% of PDMPs, with the remaining tracking II-IV. Drug-related elements captured in crash reports varied considerably by state. Eighty-six percent of states document the type of drug test administered; however, 54% of states only record whether a drug test was positive or negative, with less than a third of states citing specific drugs. Collection of personal identifiers is required in all crash and PDMP databases, suggesting high potential for effective linkage.</p> <p><i>Conclusions:</i> Lack of integration between crash and PDMP databases hinders advancement of the evidence base on the interconnected causes of unintentional injury death. While crash reports and PDMPs possess their own sets of strengths and weaknesses, linkage of these two data sources could fill critical research gaps.</p>			
17. Key Words Opioid; Road Safety; Police Crash Data; PDMP; Impairment		18. Distribution Statement	
19. Security Classif. (of this report) Unclassified	20. Security Classif. (of this page) Unclassified	21. No. of Pages 15	22. Price

Contents

Opioids at the health and transportation safety nexus	1
U.S. DOT Disclaimer	2
Acknowledgement of Sponsorship	2
Introduction	5
Population-Based Surveillance on Drug Dispensing and Crashes	5
Prescription Drug Monitoring Programs	5
Road Traffic Crash Reports	7
Crash and Drug-Related Surveillance Data Linkage.....	8
Prior Examples	8
Potential for PDMP-Crash Data Linkage and Transferable Linkage Lessons	8
Insights to Inform Public Health and Safety Practice.....	9
Conclusions	10
Heading Two	Error! Bookmark not defined.
Heading Three	Error! Bookmark not defined.
Heading Three	Error! Bookmark not defined.
Heading Two	Error! Bookmark not defined.
Heading Three	Error! Bookmark not defined.

Introduction

Road traffic injuries and drug overdoses are the two leading causes of injury death in the U.S. (Centers for Disease Control and Prevention 2019) In 2017, these two mechanisms were responsible for more than 100,000 deaths. Perhaps more importantly, these two leading causes of injury are closely interconnected. Opioids and other drugs affect driving abilities (e.g., reaction time, alertness, concentration) and crash-related injuries often result in opioid prescribing (Pergolizzi et al. 2018; Berecki-Gisolf et al. 2016), creating a potential feedback loop from crash to injury to pain to opioid use and back to crash. At any given time, about 20% of drivers have a potentially impairing drug in their system (National Highway Traffic Safety Administration 2015).

Despite the magnitude of these public health problems, very little is known about the interactions between transportation and opioid use. Research has generally relied on isolated trend and risk factor analyses (Chihuri and Li 2017; Gjerde, Strand, and Morland 2015). As a result, our picture of connections between these two public health problems is incomplete. Studies to date have largely used fatal crash data to estimate relationships between opioids and other drugs and crash culpability. This work has been limited by toxicological data quality, little contextual information on road users' health, and a narrow focus on fatal crashes only. Likewise, studies that have examined drug-involved crashes in traditional health care databases generally include little information about crash circumstances (Gibson et al. 2009; Quinn et al. 2017). These isolated or "siloe" perspectives limit an understanding of the connections between opioid and traffic crashes and limit abilities to develop solutions. This article examines the linkage potential of two rich population-based data systems, prescription drug monitoring programs (PDMP) and police-reported crash databases, and identifies knowledge gaps amenable to data linkage studies.

Population-Based Surveillance on Drug Dispensing and Crashes

We first provide an overview of PDMP and crash data system attributes across the U.S. We then follow with a discussion of PDMP-crash data linkage feasibility, potentially transferable lessons from other linkage efforts, and knowledge gaps that could be addressed using PDMP-crash linked data.

Prescription Drug Monitoring Programs

PDMPs are state-level databases designed to facilitate the collection, monitoring, and analysis of data on dispensed controlled substances. By aggregating patient, pharmacy, prescriber, and prescription data entered by pharmacies, PDMPs are primarily used to enhance patient care and support development of prevention and treatment strategies for drug misuse. PDMPs currently exist in all 50 states and the District of Columbia (Missouri has a partial, not statewide, PDMP), among which 65% (n=33) were operational prior to 2010 (Table 1). Controlled substances tracked by PDMPs are classified by the Drug Enforcement Agency into "schedules" according to their potential harm, ranging from Schedule II (high misuse and addiction potential, e.g., methadone) to Schedule V (low misuse and addiction potential, e.g., cough medications with low codeine levels). Controlled substances classified as Schedules II-V are monitored by 76% (n=39) of PDMPs, while the remaining 24% (n=12) monitor Schedules II-IV. Several PDMPs also monitor other, non-scheduled drugs of concern (e.g., butalbital, pseudoephedrine). Schedule I controlled substances include illegal substances with no accepted medical use and are not tracked in PDMPs.

All state PDMPs require detailed dispensing records, including prescription and fill dates, quantity dispensed, days supply, and dosage. Also required in all PDMP databases is the collection of personally identifiable information (PII), including first and last name, address, and date of birth, with some capturing other forms of identification (i.e., driver's license number, social security number). Nearly all PDMPs (94%, n=48) are authorized to release data for research purposes, and law enforcement are often able to gain PDMP access either during an active investigation (71%, n=36) or during court proceedings (29%, n=15). In addition, Utah mandates that substance-related driving convictions (e.g., driving while impaired) be entered in the PDMP.

State-level details regarding attributes and specific data elements collected by PDMPs are provided in Appendix Table 1.

Table 1. Select attributes of prescription drug monitoring programs^a pertinent to crash report linkage, investigation, and analyses (n=51)^b

Attribute	N (%)
Year Prescription Drug Monitoring Program (PDMP) first operational	
<1990	9 (18)
1990-1999	7 (14)
2000-2009	17 (33)
2010-2017	18 (35)
Agency responsible for PDMP administration	
Pharmacy Board	20 (39)
Department of Health	17 (33)
Professional Licensing Agency	6 (12)
Law Enforcement Agency	4 (8)
Substance Abuse Agency	3 (6)
Consumer Protection Agency	1 (2)
Authority to release PDMP data for research	
No authority to release	3 (6)
Authorized to release	48 (94)
Law enforcement access to data	
Access if active investigation	36 (71)
Access if court process (e.g., court order, subpoena, search warrant)	15 (29)
Types of data available to law enforcement	
Patient, prescriber, dispenser histories	42 (82)
Patient and prescriber histories	6 (12)
Patient history	1 (2)
Unknown	2 (4)
Controlled substances monitored ^c	
Schedules II-IV	12 (24)
Schedules II-V	39 (76)
Requirement that substance-related driving convictions be included in PDMP	
Yes	1 (2)
No	50 (98)

^a Missouri's PDMP does not span the entire state.

^b Includes 50 U.S. states and the District of Columbia

^c Several PDMPs also monitor other specific drugs of concern that might fall outside of these classes (e.g., pseudoephedrine); see Appendix for specific information by state.

Road Traffic Crash Reports

Crash reports provide the primary data source for road safety research. Crash reports are completed by law enforcement officers at the crash scene and include individual, roadway, and vehicle information. Data generally follow a standard format, based on the Model Minimum Uniform Crash Criteria (MMUCC) (MMUCC 2012). PII often include first and last name, address, date of birth, and driver's license number.

While many crash report data elements are consistent across states, including detailed information on vehicle characteristics, roadway design, environmental characteristics, and persons' actions at the time of the crash (e.g., ran a red light) and injury status, specific documentation regarding drug involvement varies considerably by state. Sixty-two percent (n=30) of state crash report forms include a field for law enforcement to document whether they suspect a driver to be under the influence of drugs at the time of the crash (Table 2). Most state crash report forms (84%; n=43) provide an opportunity for the officer to document the type of drug test administered (e.g., blood, urine, drug recognition expert evaluation). Results are most often captured as a positive or negative indication for drug involvement (55%, n=28 states). Additionally, 65% (n=33) of crash report forms provide a field for officers to indicate whether drugs involved were prescriptions or illicit drugs. Completion rates for these fields vary by state and time, and importantly, are germane only to the post-crash population. Scientific inference is severely limited in the absence of population-based data on drug dispensing and use in the general population of all drivers (crash and non-crash). State-level details regarding specific drug-related data elements captured in crash reports is provided in Appendix Table 2.

Table 2. Select attributes of crash report forms pertinent to linked analyses with prescription drug monitoring program data (n=51)^a

Attribute	N (%)
Year of last crash report form update	
2005-2009	16 (31)
2010-2014	23 (45)
2015-2018	12 (24)
Field to document whether drugs were suspected ^b	
Yes	30 (59)
Unknown or not mentioned	21 (41)
Field to document type of drug test administered ^b	
Yes	43 (84)
Unknown or not mentioned	8 (16)
Detail of drug test result documentation ^{b,c}	
Positive or negative indication for drug involvement	28 (55)
Drugs selected from a pre-defined list	11 (22)
Narrative, supplemental document, or drug recognition expert report	4 (8)
Unknown or not mentioned	8 (16)
Field for whether prescription or illicit drugs involved ^b	
Yes	33 (65)
Unknown or not mentioned	18 (35)

^a Includes 50 U.S. states and the District of Columbia

^b Documents whether a field is available on crash report form to capture these elements; completeness varies by state.

^c Generally captured in terms of broad categories; see Appendix for specific information by state.

Note: State laws and practices may vary with respect to release of data for linkage and research purposes and is an important state-specific consideration.

Crash and Drug-Related Surveillance Data Linkage

Prior Examples

Several states have initiated or established data systems linking PDMP data to other sources of public health information, providing rich perspectives and information on the opioid epidemic (Slavova et al. 2017; Massachusetts Department of Public Health 2017). Notable examples include comprehensive data systems in Massachusetts and Tennessee. Massachusetts passed legislation in 2015 to facilitate data sharing across five government agencies and ten data sources related to the opioid crisis, providing an unprecedented look at opioid prescribing, addiction, treatment, and overdose impacts across the state (Massachusetts Department of Public Health 2017). Similarly, legislation in Tennessee facilitated the development of a data warehouse that stores and links multiple sources of health and prescription data to improve understanding of drug-related issues.¹¹ In addition to these comprehensive and ongoing data systems, other states have conducted one-time linkages between state PDMPs and emergency department data, hospital admissions, criminal justice data, health insurance claims data, vital statistics records, medical examiner data, or Veteran's Health Administration data to answer novel questions and guide policy (Naumann et al. 2018; Austin et al. 2017; Dasgupta et al. 2016; Carlson et al. 2018; Deyo et al. 2017; Geissert et al. 2018; Hartung et al. 2017; Fink et al. 2018; Nechuta et al. 2018).

From a road safety perspective, there have been efforts to take a more comprehensive look at contributors to and burden of crashes. In New Jersey, a comprehensive crash outcomes database was established and includes licensing, crash report, and citation data (Curry et al. 2017). The system is also currently expanding to include sources of health data (hospital discharge data, vital records), providing a unique view of causes and consequences of crashes (Curry 2018). Multiple states have used probabilistic methods to link crash and injury outcome data (e.g., the Crash Outcome Data Evaluation System) to gain a more complete understanding of crash impacts and to support transportation policy.¹⁷ Finally, numerous one-time linkage efforts have combined crash data with other state databases to explore individual risk factors, subpopulations, or trends in road traffic crashes (Bunn et al. 2013; Conderino et al. 2017; Thomas et al. 2012; Gonzalez et al. 2009).

Potential for PDMP-Crash Data Linkage and Transferable Linkage Lessons

Our assessment of state PDMP and crash database attributes (Tables 1 and 2) indicates that linkage of these two sources is likely feasible in many states with respect to statutory requirements and identifiers available for potential linkage. Additionally, linkage efforts underway in states highlight both the readiness in many states, as well as transferable lessons to potential crash-PDMP data linkage, including: 1) many states have either a comprehensive data system to build from or technical or political experiences to draw from; 2) political will and legislation serve a critical role in fostering linkage processes and creating sustainable data system structures (Massachusetts Department of Public Health 2017; Office of Informatics and Analytics 2019); and 3) coalitions of data owners and users can ensure accurate and highly useful research and continued linkage support (Milani et al. 2015). We discuss each of these aspects below.

First, linkage requires high-quality matching variables, thorough knowledge about sources to be linked (e.g., data quality considerations), and best practice linkage approaches. In addition to these technical issues, ongoing linkage necessitates trusted relationships between agencies involved. We found many states had a successful history of linkage with PDMP or crash records, suggesting potential foundations to leverage from both technical and political perspectives. Second, many sustainable linked data systems are backed by political will and/or policy, which can help ensure stable funding streams for linkage activities and active use of the data (Office of Informatics and Analytics 2019; Massachusetts Department of Public Health 2017). While such opportunities can be difficult to create and foster, there is currently considerable political attention on PDMP data systems, including refining information collected, mandating their use, and bringing in other

data sources to increase overall utility. Public health and road safety partners should explore these efforts as potential windows of opportunity to elevate calls for crash data linkage.

Sustainability of linked data systems often includes the establishment of an active coalition that includes data owners and other key stakeholders, providing a forum to regularly demonstrate the tangible benefits of linkage and discuss future analytic directions (Milani et al. 2015). In some states, a promising approach could involve integrating crash records experts and PDMP data owners into existing, active opioid or road safety coalitions. In other states, stakeholder integration may be more straightforward, e.g., in four states, law enforcement manages both PDMP and crash records (Table 1).

Insights to Inform Public Health and Safety Practice

PDMP-crash data linkage provides an opportunity to address several research gaps and ultimately improve clinical, public health, and road safety practice (e.g., informing Drug Recognition Expert training and practice) (Box 1). Linkage can increase understanding of risk factors and context surrounding crashes as well as provide insights regarding consequences of these events. For example, through a comprehensive understanding of drivers' opioid and other controlled substance regimens prior to crash events, researchers can gain a sense of which substances are most often implicated in crashes and which individual drugs or drug combinations warrant further risk analyses to ultimately inform the evidence base on impairment. Historically, our understanding of substance-impaired driving has been hampered by availability and quality of data. While PDMP-crash data linkage does not solve all impaired driving research limitations (e.g., lack of personal exposure/miles travelled data), it provides a valuable opportunity to illuminate, at a population level, specific substances, combinations of substances, and dose and duration factors deserving more detailed consideration.

Box 1. Pressing research questions best answered using linked crash reports and prescription drug monitoring program data

- What are the prescription opioid and controlled substance histories and trajectories of those involved in crashes (of all severity levels) compared to those who do not crash?
- How do crash rates for those on chronic opioid and other controlled substance regimens compare to those on short-term regimens or non-users?
- Which specific opioid or other controlled substance types, dosages, and combinations are associated with increased rates of road traffic crashes?
- How often are persons of different crash-related injury severities dispensed opioids following a crash and at what level (e.g., dose, days' supply)?
- How often do crashes or other traffic convictions trigger entry into opioid (or other substance) use disorder treatment (e.g., initiation of buprenorphine treatment)?
- Do different crash and injury typologies result in different levels of opioid prescribing?

In addition to understanding drug-related trajectories leading up to crash events, PDMP-crash data linkage can provide a critical perspective on crash effects, with implications for tertiary prevention following a crash. For example, one could examine how often individuals experiencing crash-related injuries are dispensed opioids and other substances and the crash and substance-related risk factors for long-term drug utilization trajectories that progress from those injuries, as well as the impacts these trajectories might then have on future crash risk. Figure 1 provides a conceptual system map of how opioid and road traffic crashes are interrelated. Each of these linkages deserves further study. Exploring prescription drug trajectories post-crash and provision of addiction treatment-related medications (e.g., buprenorphine for opioid addiction) can advance understanding of the extent and ways in which crashes alter drug use and connection to treatment (e.g., through drug courts or other channels). While preventing crashes (primary prevention) is of foremost

importance, understanding how post-crash pathways might be beneficially altered and repeated injury minimized is critical (tertiary prevention). Ultimately, isolating the impacts of specific prescription drug regimens on crash risk can directly inform patient drug counselling and interventions, including consideration of alternate travel modes.




Figure 1. System map linking Road Traffic Crashes with Opioid Use

Conclusions

Crash and PDMP population-based data systems contain rich information on prescription drug histories and detailed crash circumstances, providing a valuable opportunity to advance understanding of prescription drug trajectories leading to crash events and effects of crashes on subsequent prescription drug patterns. Unfortunately, routine, on-going linkage of these data sources is lacking. However, many states have strong linkage foundations in opioid or road safety arenas, providing technical and political proficiencies to leverage. A complete and unbiased exploration of opioid-impaired driving and its consequences will require comprehensive health, substance, and travel exposure data. PDMP-crash data linkage can help fill one important piece of this puzzle and yield insights regarding the complex interplay between opioids and driving.



730 Martin Luther King Jr. Blvd.
Suite 300
Chapel Hill, NC 27599-3430
info@roadsafety.unc.edu

www.roadsafety.unc.edu

References

- Austin, A. E., S. K. Proescholdbell, K. E. Creppage, and A. Asbun. 2017. "Characteristics of self-inflicted drug overdose deaths in North Carolina." *Drug Alcohol Depend* 181: 44-49. <https://doi.org/10.1016/j.drugalcdep.2017.09.014>. https://ac.els-cdn.com/S0376871617304969/1-s2.0-S0376871617304969-main.pdf?_tid=d793a9e7-c200-4109-8821-de0ca416a38d&acdnat=1545424871_e01167d60a8cbdc4d3f73be7443b0e70.
- Berecki-Gisolf, J., B. Hassani-Mahmooei, A. Collie, and R. McClure. 2016. "Prescription Opioid and Benzodiazepine Use After Road Traffic Injury." *Pain Med* 17 (2): 304-13. <https://doi.org/10.1111/pme.12890>.
- Bunn, T., M. Singleton, V. Nicholson, and S. Slavova. 2013. "Concordance of motor vehicle crash, emergency department, and inpatient hospitalization data sets in the identification of drugs in injured drivers." *Traffic Inj Prev* 14 (7): 680-9. <https://doi.org/10.1080/15389588.2012.757310>.
- Carlson, K. F., T. A. Gilbert, B. J. Morasco, D. Wright, J. V. Otterloo, A. Herrndorf, and L. J. Cook. 2018. "Linkage of VA and State Prescription Drug Monitoring Program Data to Examine Concurrent Opioid and Sedative-Hypnotic Prescriptions among Veterans." *Health Serv Res* 53 Suppl 3: 5285-5308. <https://doi.org/10.1111/1475-6773.13025>. <https://onlinelibrary.wiley.com/doi/abs/10.1111/1475-6773.13025>.
- Centers for Disease Control and Prevention. 2019. "Wide-ranging Online Data for Epidemiologic Research: National Vital Statistics System mortality data." <https://wonder.cdc.gov>.
- Chihuri, S., and G. Li. 2017. "Use of prescription opioids and motor vehicle crashes: A meta analysis." *Accid Anal Prev* 109: 123-131. <https://doi.org/10.1016/j.aap.2017.10.004>.
- Conderino, S., L. Fung, S. Sedlar, and J. M. Norton. 2017. "Linkage of traffic crash and hospitalization records with limited identifiers for enhanced public health surveillance." *Accid Anal Prev* 101: 117-123. <https://doi.org/10.1016/j.aap.2017.02.011>.
- Curry, Allison E. 2018. "Catalyzing young driver research via data linkage: development of a comprehensive traffic safety data warehouse." https://projectreporter.nih.gov/project_info_description.cfm?aid=9533637&icde=44182665&ddparam=&ddvalue=&ddsub=&cr=2&csb=default&cs=ASC&pball=.
- Curry, Allison E., Kristina B. Metzger, Melissa R. Pfeiffer, Michael R. Elliott, Flaura K. Winston, and Thomas J. Power. 2017. "Motor Vehicle Crash Risk Among Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder." *JAMA Pediatrics* 171 (8): 756-763. <https://doi.org/10.1001/jamapediatrics.2017.0910>. <https://doi.org/10.1001/jamapediatrics.2017.0910>.
- Dasgupta, Nabarun, Michele Jonsson Funk, Scott Proescholdbell, Annie Hirsch, Kurt M. Ribisl, and Steve Marshall. 2016. "Cohort Study of the Impact of High-dose Opioid Analgesics on Overdose Mortality." *Pain Medicine* 17 (1): 85-98. <https://doi.org/10.1111/pme.12907>. <http://dx.doi.org/10.1111/pme.12907>.
- Deyo, R. A., S. E. Hallvik, C. Hildebran, M. Marino, E. Dexter, J. M. Irvine, N. O'Kane, J. Van Otterloo, D. A. Wright, G. Leichtling, and L. M. Millet. 2017. "Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naive Patients: A Statewide Retrospective Cohort Study." *J Gen Intern Med* 32 (1): 21-27. <https://doi.org/10.1007/s11606-016-3810-3>. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215151/pdf/11606_2016_Article_3810.pdf.
- Fink, P. B., R. A. Deyo, S. E. Hallvik, and C. Hildebran. 2018. "Opioid Prescribing Patterns and Patient Outcomes by Prescriber Type in the Oregon Prescription Drug Monitoring Program." *Pain Med* 19 (12): 2481-2486. <https://doi.org/10.1093/pm/pnx283>. https://watermark.silverchair.com/pnx283.pdf?token=AQECAHi208BE49Ooan9kKhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAnswggJ3BgkqhkiG9w0BBwagggJoMIICZAIBADCCAI0GCSqGSIb3DQEHATAeBgIghkqBZQMEAS4wEQQMhUxFBGLWjKyJdp4JAgEQgIIClkGJj_MIPWfYuUNcnKF-oSGhFjLwJs83YI8Ubj1o_nCqzalseP_lcmLQSUK-0_QeQX5G5E3GUsrgTbivtNENQeSOZtUFjK6Pi5KPhq5ulSf1NGs5lCy9uLpxz7avjZNb8eBvjOcu5qUbNEBytamQWbvIE_9RgnchsPMCI00ia2W_nriuP1TDR_0DKW5D8WMG_6ENHDSogg-6v1blSMsx8R8WezcbqC_MFv4DgRklajUVD_THCEPF7MTvDdv-olfXdKPxsRpgk_CzEimA5-CQnQgZkkHolbowB9qx6Sm1mFmZkywOhf6rYwzr2eP2dzuFi7qwSymTDZR1CpjlvNQMNfmifRS8UwAu88btEgwHb80_Abnl0l6mUHAEepCDQPL4DdfK9ytsl_BM8K7nAwfmo-

- [c2CirbSWb1RdUNcwWlqvRXbpOh_tuhFPSkkw4dYC-YPHtHOI-3XUi8aC8Dtrc4qNAbRH2-K_12UjUhpWP2eT_tclT6lZO_OR7hMT_I73GoudQ3trMs-hrq_740aG_aDtyODCV0205K038Xq-rmPfJscnLioslpx5aqOZWo7y9KE5oWv4lJbelDZmZnmZOsjul-9pqOhgTCSwnG-rL430bNbFub6sIAFg7wucDnBGP-JFTlp001pdqb0I3KZihoSViV4mreHSnRG-ZD7M4PyhWLdtaYzTC2hTgG4hDm0ZvRKlcq1NafvT2xK2wYNbh0slSdCUi1BZ7HOrhZNbcTO.](https://doi.org/10.1097/j.pain.0000000000001078)
- Geissert, P., S. Hallvik, J. Van Otterloo, N. O'Kane, L. Alley, J. Carson, G. Leichtling, C. Hildebran, 3rd, W. Wakeland, and R. A. Deyo. 2018. "High-risk prescribing and opioid overdose: prospects for prescription drug monitoring program-based proactive alerts." *Pain* 159 (1): 150-156. <https://doi.org/10.1097/j.pain.0000000000001078>.
- Gibson, Jack E., Richard B. Hubbard, Christopher J. P. Smith, Laila J. Tata, John R. Britton, and Andrew W. Fogarty. 2009. "Use of Self-controlled Analytical Techniques to Assess the Association Between Use of Prescription Medications and the Risk of Motor Vehicle Crashes." *American Journal of Epidemiology* 169 (6): 761-768. <https://doi.org/10.1093/aje/kwn364>. <https://doi.org/10.1093/aje/kwn364>.
- Gjerde, H., M. C. Strand, and J. Morland. 2015. "Driving Under the Influence of Non-Alcohol Drugs--An Update Part I: Epidemiological Studies." *Forensic Sci Rev* 27 (2): 89-113.
- Gonzalez, Richard P., Glenn R. Cummings, Herbert A. Phelan, Madhuri S. Mulekar, and Charles B. Rodning. 2009. "Does increased emergency medical services prehospital time affect patient mortality in rural motor vehicle crashes? A statewide analysis." *The American Journal of Surgery* 197 (1): 30-34. <https://doi.org/https://doi.org/10.1016/j.amjsurg.2007.11.018>. <http://www.sciencedirect.com/science/article/pii/S0002961008002699>.
- Hartung, D. M., S. M. Ahmed, L. Middleton, J. Van Otterloo, K. Zhang, S. Keast, H. Kim, K. Johnston, and R. A. Deyo. 2017. "Using prescription monitoring program data to characterize out-of-pocket payments for opioid prescriptions in a state Medicaid program." *Pharmacoepidemiol Drug Saf*. <https://doi.org/10.1002/pds.4254>. <http://onlinelibrary.wiley.com/doi/10.1002/pds.4254/abstract>.
- Massachusetts Department of Public Health. 2017. "Legislative Report: Chapter 55 Opioid Overdose Study." <https://www.mass.gov/files/documents/2017/08/31/legislative-report-chapter-55-aug-2017.pdf>.
- Milani, J., J. Kindelberger, G. Bergen, E. J. Novicki, C. Burch, S. M. Ho, and B. A. West. 2015. "Assessment of characteristics of state data linkage systems. (Report No. DOT HS 812 180)." <https://crashstats.nhtsa.dot.gov/Api/Public/ViewPublication/812180>.
- MMUCC. 2012. "Model Minimum Uniform Crash Criteria." *DOT HS 811*: 631.
- National Highway Traffic Safety Administration. 2015. "Results of the 2013–2014 National Roadside Survey of Alcohol and Drug Use by Drivers." *DOT HS 812 118*. https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/812118-roadside_survey_2014.pdf.
- Naumann, R. B., S. W. Marshall, J. L. Lund, N. C. Gottfredson, C. Ringwalt, and A. C. Skinner. 2018. "Evaluating short- and long-term impacts of a Medicaid "lock-in" program on opioid and benzodiazepine prescriptions dispensed to beneficiaries." *Drug & Alcohol Dependence* 182: 112-119.
- Nechuta, S. J., B. D. Tyndall, S. Mukhopadhyay, and M. L. McPheeters. 2018. "Sociodemographic factors, prescription history and opioid overdose deaths: a statewide analysis using linked PDMP and mortality data." *Drug Alcohol Depend* 190: 62-71. <https://doi.org/10.1016/j.drugalcdep.2018.05.004>. https://ac.els-cdn.com/S0376871618303193/1-s2.0-S0376871618303193-main.pdf?_tid=fa712310-5de8-49ab-ab27-b0483488a145&acdnat=1545424855_717b0b4bf28f4d4c8c8cb060d931b0d4.
- Office of Informatics and Analytics, Tennessee Department of Health. 2019. "Tennessee's Annual Overdose Report: Understanding and responding to the opioid epidemic in Tennessee using Mortality, Morbidity, and Prescription Data." https://www.tn.gov/content/dam/tn/health/documents/pdo/2019_Report.pdf.
- Pergolizzi, J. V., Jr., R. Taylor, Jr., J. A. LeQuang, J. Bisney, R. B. Raffa, F. Pergolizzi, D. Colucci, and L. Batastini. 2018. "Driving under the influence of opioids: What prescribers should know." *J Opioid Manag* 14 (6): 415-427. <https://doi.org/10.5055/jom.2018.0474>.
- Quinn, Patrick D., Kwan Hur, Zheng Chang, Erin E. Krebs, Matthew J. Bair, Eric L. Scott, Martin E. Rickert, Robert D. Gibbons, Kurt Kroenke, and Brian M. D'Onofrio. 2017. "Incident and long-term opioid therapy among patients with psychiatric conditions and medications: a national study of commercial health care claims." *Pain* 158 (1): 140-148. <https://doi.org/10.1097/j.pain.0000000000000730>. <https://www.ncbi.nlm.nih.gov/pubmed/27984526>.

<https://www.ncbi.nlm.nih.gov/pmc/PMC5171228/>.

Slavova, Svetla, Terry L. Bunn, Sarah L. Hargrove, Tracey Corey, and Van Ingram. 2017. "Linking Death Certificates, Postmortem Toxicology, and Prescription History Data for Better Identification of Populations at Increased Risk for Drug Intoxication Deaths." *Pharmaceutical Medicine* 31 (3): 155-165. <https://doi.org/10.1007/s40290-017-0185-7>. <https://doi.org/10.1007/s40290-017-0185-7>

<https://link.springer.com/article/10.1007%2Fs40290-017-0185-7>.

Thomas, Andrea M., Steven M. Thygeson, Ray M. Merrill, and Lawrence J. Cook. 2012. "Identifying Work-Related Motor Vehicle Crashes in Multiple Databases." *Traffic Injury Prevention* 13 (4): 348-354. <https://doi.org/10.1080/15389588.2012.658480>. <https://doi.org/10.1080/15389588.2012.658480>.

Appendix

Details on PDMP-related data abstraction, crash record-related data abstraction, and Appendix Tables 1 and 2 can be found in the attached Appendix files.

Appendix Table 1. Attributes of prescription drug monitoring programs pertinent to crash report linkage, investigation, and analyses by state and the District of Columbia (n=51)

Appendix Table 2. Attributes of crash report databases pertinent to linked analyses with prescription drug monitoring program data by state and the District of Columbia (n=51)